Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26357624
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
MicroRNAs in Drug-induced Liver Injury
#MMPMID26357624
Li LM
; Wang D
; Zen K
J Clin Transl Hepatol
2014[Sep]; 2
(3
): 162-9
PMID26357624
show ga
Drug-induced liver injury (DILI) is a leading cause of acute liver failure, and a
major reason for the recall of marketed drugs. Detection of potential liver
injury is a challenge for clinical management and preclinical drug safety
studies, as well as a great obstacle to the development of new, effective and
safe drugs. Currently, serum levels of alanine and aspartate aminotransferases
are the gold standard for evaluating liver injury. However, these levels are
assessed by nonspecific, insensitive, and non-predictive tests, and often result
in false-positive results. Therefore, there is an urgent need for better DILI
biomarkers to guide risk assessment and patient management. The discovery of
microRNAs (miRNAs) as a new class of gene expression regulators has triggered an
explosion of research, particularly on the measurement of miRNAs in various body
fluids as biomarkers for many human diseases. The properties of miRNA-based
biomarkers, such as tissue specificity and high stability and sensitivity,
suggest they could be used as novel, minimally invasive and stable DILI
biomarkers. In the current review, we summarize recent progress concerning the
role of miRNAs in diagnosing and monitoring both clinical and preclinical DILI,
and discuss the main advantages and challenges of miRNAs as novel DILI
biomarkers.
free
free
free
